Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2014, Article ID 473170, 8 pages
http://dx.doi.org/10.1155/2014/473170
Review Article

Occurrence of Autoimmune Diseases Related to the Vaccine against Yellow Fever

1Faculdade de Medicina, Universidade de Brasília, Brasília, DF, Brazil
2CRDF, SHLN Bloco L Centro Cínico Norte II, 70910-900 Brasília, DF, Brazil
3Hospital Universitário Professor Edgard Santos da Universidade Federal da Bahia, 70390-700 Salvador, BA, Brazil
4Coordenação de Pesquisa da Fundação Oswaldo Cruz (FIOCRUZ), 41810-080 Brasília, DF, Brazil
5Laboratório de Biomarcadores de Diagnóstico e Monitoração do Centro de Pesquisas René Rachou, FIOCRUZ, 21040-900 Belo Horizonte, MG, Brazil

Received 30 July 2014; Revised 8 September 2014; Accepted 22 September 2014; Published 22 October 2014

Academic Editor: Ricard Cervera

Copyright © 2014 Ana Cristina Vanderley Oliveira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. L. Gardner and K. D. Ryman, “Yellow fever: a reemerging threat,” Clinics in Laboratory Medicine, vol. 30, no. 1, pp. 237–260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. P. F. Vasconcelos, “Yellow fever,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 36, no. 2, pp. 275–293, 2003. View at Google Scholar
  3. J. E. Staples and T. P. Monath, “Yellow fever: 100 Years of discovery,” Journal of the American Medical Association, vol. 300, no. 8, pp. 960–962, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. W. H. Organization, Yellow fever, Fact Sheet no. 100, 2011, http://www.who.int/mediacentre/factsheets/fs100/en/.
  5. A. C. Lopes, Tratado de Clínica Médica, 2nd edition, 2009.
  6. C. Domingo and M. Niedrig, “Safety of 17D derived yellow fever vaccines,” Expert Opinion on Drug Safety, vol. 8, no. 2, pp. 211–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. E. D. Barnett, “Yellow fever: epidemiology and prevention,” Clinical Infectious Diseases, vol. 44, no. 6, pp. 850–856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. D. Barrett and D. E. Teuwen, “Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place?” Current Opinion in Immunology, vol. 21, no. 3, pp. 308–313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. E. B. Hayes, “Is it time for a new yellow fever vaccine?” Vaccine, vol. 28, no. 51, pp. 8073–8076, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. P. Grobusch, A. Goorhuis, R. W. Wieten et al., “Yellow fever revaccination guidelines change—a decision too feverish?” Clinical Microbiology and Infection, vol. 19, no. 10, pp. 885–886, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. W. McMahon, R. B. Eidex, A. A. Marfin et al., “Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases,” Vaccine, vol. 25, no. 10, pp. 1727–1734, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Tishler and Y. Shoenfeld, “Vaccination may be associated with autoimmune diseases,” The Israel Medical Association Journal, vol. 6, no. 7, pp. 430–432, 2004. View at Google Scholar · View at Scopus
  13. H. Orbach, N. Agmon-Levin, and G. Zandman-Goddard, “Vaccines and autoimmune diseases of the adult,” Discovery Medicine, vol. 9, no. 45, pp. 90–97, 2010. View at Google Scholar · View at Scopus
  14. P. Santaguida and P. Raina, “McMaster Quality Assessment Scale of Harms (McHarm) for primary studies,” http://hiru.mcmaster.ca/epc/mcharm.pdf.
  15. H. Miller, W. Cendrowski, and K. Shapira, “Multiple sclerosis and vaccination,” British Medical Journal, vol. 2, no. 546, pp. 210–213, 1967. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Perumalswami, L. Peng, and J. A. Odin, “Vaccination as a triggering event for autoimmune hepatitis,” Seminars in Liver Disease, vol. 29, no. 3, pp. 331–334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Schmöeller, M. W. Keiserman, H. L. Staub, F. P. Velho, and M. De Fátima Grohe, “Yellow fever vaccination and kawasaki disease,” Pediatric Infectious Disease Journal, vol. 28, no. 11, pp. 1037–1038, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Stangos, M. Zaninetti, I. Petropoulos, E. Baglivo, and C. Pournaras, “Multiple evanescent white dot syndrome following simultaneous hepatitis-A and yellow fever vaccination,” Ocular Immunology and Inflammation, vol. 14, no. 5, pp. 301–304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Vital, A. Vital, G. Gbikpi-Benissan et al., “Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases,” Journal of the Peripheral Nervous System, vol. 7, no. 3, pp. 163–167, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Merlo, R. Steffen, T. Landis, T. Tsai, and N. Karabatsos, “Possible association of encephalitis and 17D yellow fever vaccination in a 29-year-old traveller,” Vaccine, vol. 11, no. 6, p. 691, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Loughlin, C. D. Marchant, W. Adams et al., “Causality assessment of adverse events reported to the vaccine adverse event reporting system (VAERS),” Vaccine, vol. 30, no. 50, pp. 7253–7259, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. O. Gout, “Vaccinations and multiple sclerosis,” Neurological Sciences, vol. 22, no. 2, pp. 151–154, 2001. View at Google Scholar
  23. D. P. Bogdanos, H. Smith, Y. Ma, H. Baum, G. Mieli-Vergani, and D. Vergani, “A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics,” Clinical and Developmental Immunology, vol. 12, no. 3, pp. 217–224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Fine, A. Fine, and E. T. Cunningham Jr., “Multiple evanescent white dot syndrome following hepatitis A vaccination,” Archives of Ophthalmology, vol. 119, no. 12, pp. 1856–1858, 2001. View at Google Scholar · View at Scopus
  25. L. M. Mota, A. C. V. Oliveira, R. A. C. Lima, L. L. Dos Santos-Neto, and P. L. Tauil, “Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 42, no. 1, pp. 23–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Löbermann, D. Boršo, I. Hilgendorf, C. Fritzsche, U. K. Zettl, and E. C. Reisinger, “Immunization in the adult immunocompromised host,” Autoimmunity Reviews, vol. 11, no. 3, pp. 212–218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Shoenfeld and N. Agmon-Levin, ““ASIA”—autoimmune/inflammatory syndrome induced by adjuvants,” Journal of Autoimmunity, vol. 36, no. 1, pp. 4–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Lerner, “Aluminum as an adjuvant in Crohn's disease induction,” Lupus, vol. 21, no. 2, pp. 231–238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Dimitrijević, I. Živković, M. Stojanović, V. Petrušić, and S. Živančević-Simonović, “Vaccine model of antiphospholipid syndrome induced by tetanus vaccine,” Lupus, vol. 21, no. 2, pp. 195–202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. E. S. Vista, S. R. Crowe, L. F. Thompson et al., “Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus,” Lupus, vol. 21, no. 2, pp. 168–174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Agmon-Levin, G. Hughes, and Y. Shoenfeld, “The spectrum of ASIA: ‘autoimmune (auto-inflammatory) syndrome induced by adjuvants’,” Lupus, vol. 21, no. 2, pp. 118–120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. L. P. Gaspar, Y. S. Mendes, A. M. Y. Yamamura et al., “Pressure-inactivated yellow fever 17DD virus: implications for vaccine development,” Journal of Virological Methods, vol. 150, no. 1-2, pp. 57–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. T. P. Monath, E. Fowler, C. T. Johnson et al., “An inactivated cell-culture vaccine against yellow fever,” The New England Journal of Medicine, vol. 364, no. 14, pp. 1326–1333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. L. Silva, L. R. Espírito-Santo, M. A. Martins et al., “Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination,” Clinical and Vaccine Immunology, vol. 17, no. 1, pp. 118–126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Vellozzi, T. Mitchell, E. Miller et al., “Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996–2004,” The American Journal of Tropical Medicine and Hygiene, vol. 75, no. 2, pp. 333–336, 2006. View at Google Scholar · View at Scopus